Total amount raised
$424 Millions
Latest funding date
Location
Transcarent has successfully raised significant funding through multiple rounds, including a Series D, with backing from notable investors such as 7wire Ventures and Human Capital. The platform offers a comprehensive, consumer-directed health and care solution for employees of self-insured employers and their families.
Keep reading to explore the intricacies of Transcarent's fundraising journey and the investors supporting this innovative healthcare platform.
What Is Transcarent?
Transcarent, founded in 2020 by Glen Tullman, is headquartered in Denver, Colorado. The company provides a consumer-directed health and care platform designed for employees of self-insured employers and their families.
Transcarent leverages software, technology, health guides, and data science to offer unbiased information, trusted guidance, and access to high-value care. Their services include benefits navigation, clinical guidance, and 24/7 on-demand care.
With a team of 251-500 employees, Transcarent aims to simplify the healthcare experience, making it easier for people to access high-quality, affordable health and care.
How Much Funding Has Transcarent Raised?
- Series A
- Amount Raised: $40M
- Date: October 2020
- Lead Investors: 7wire Ventures, General Catalyst
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish the platform and begin scaling operations.
- Series B
- Amount Raised: $58M
- Date: June 2021
- Lead Investors: 7wire Ventures, General Catalyst
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand service offerings and enhance technology infrastructure.
- Series C
- Amount Raised: $200M
- Date: January 2022
- Lead Investors: Human Capital, Kinnevik
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate market expansion and integrate new health programs.
- Series D
- Amount Raised: $126M
- Date: May 2024
- Lead Investors: General Catalyst, 7wire Ventures
- Valuation at Round: $2.2 billion
- Motivation Behind the Round: To enhance AI capabilities and support commercial growth.
Total amount raised: $424M. Current valuation: $2.2 billion.
Key Investors
- 7wire Ventures
- Details: 7wire Ventures is a venture capital firm co-founded by Glen Tullman. The firm focuses on investing in early-stage digital health companies that aim to improve healthcare delivery and reduce costs.
- Investment Focus Areas: Health Care, Digital Health, Consumer Health
- Notable Investments: Livongo, Bright Health, NOCD
- Human Capital
- Details: Human Capital is a venture capital firm that invests in and builds technology companies. They focus on supporting startups with strong engineering teams.
- Investment Focus Areas: Technology, Software, Human Resources
- Notable Investments: Brex, Anduril, Snowflake
- General Catalyst
- Details: General Catalyst is a venture capital firm that invests in early-stage and growth-stage companies. They focus on building long-term partnerships with entrepreneurs and providing them with the resources and support needed to grow their businesses.
- Investment Focus Areas: Technology, Healthcare, Consumer Services
- Notable Investments: Airbnb, Stripe, Snap Inc.
- Kinnevik
- Details: Kinnevik is an investment company focused on building digital consumer businesses. They invest in companies that aim to disrupt traditional industries through innovative solutions.
- Investment Focus Areas: Digital Consumer Brands, Financial Services, Healthcare, Telecommunications
- Notable Investments: Zalando, Tele2, Babylon Health
- Threshold Ventures
- Details: Threshold Ventures, formerly known as DFJ, is a venture capital firm that invests in early-stage technology companies. They focus on partnering with entrepreneurs to build impactful companies.
- Investment Focus Areas: Technology, Healthcare, Consumer Sectors
- Notable Investments: Tesla, SpaceX, Box
What's Next for Transcarent?
Transcarent stands at the cusp of significant growth opportunities, driven by the increasing demand for accessible and affordable healthcare solutions. With a recent $126 million investment, the company is poised to enhance its AI capabilities and expand its service offerings. The digital health market's projected growth to $7.2 trillion by 2031 underscores the vast potential for Transcarent to scale its operations and impact.
Future fundraising efforts seem promising, given the strong investor confidence demonstrated in the Series D round. As Transcarent continues to innovate and expand, additional funding rounds could support further technological advancements and market reach. Strategic partnerships and acquisitions may also play a crucial role in bolstering the company's growth trajectory.
However, Transcarent may face challenges such as navigating regulatory complexities, ensuring data privacy, and maintaining service quality amidst rapid expansion. Competition from other digital health startups and established providers will also be a significant hurdle. Despite these challenges, Transcarent's commitment to simplifying healthcare access and reducing costs positions it well for continued success.
Use Clay to Get Funding Data
Sales professionals, take your business intelligence to the next level by leveraging Clay's platform. With Clay, you can access comprehensive fundraising data on companies like Transcarent and gather other critical business insights to drive your sales strategy.
Don't miss out on this opportunity—sign up for free today and start unlocking valuable data to boost your sales performance.
